IP Library Granted Patent US 10,421,724
Granted Patent B2
US 10,421,724 · App. 15/995,813 · Granted Sep 24, 2019

Compositions for preventing and/or treating degenerative disorders of the central nervous system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,421,724
App. No.
15/995,813
Granted
Sep 24, 2019
Kind
B2
Abstract

The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.

Claims (45)

1. A compound of Formula III:

wherein:

R 1 is C(R 2 )(R 3 )(R 4 );

R 2 is hydrogen, —OH or halogen;

R 3 is hydrogen, —OH, halogen or CH 3 ;

R 4 is halogen, CH 3 , phenyl, fluorophenyl, methylphenyl, or cyclohexylmethyl, wherein when R 4 is a halogen both R 2 and R 3 cannot be hydrogen;

R 3 and R 4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;

R 7 is —OH or halogen; and

R 8 is hydrogen, halogen or —CH 3 ,

provided that R 2 and R 3 cannot both be hydrogen when R 4 is a halogen or phenyl, R 7 is —OH and R 8 is hydrogen,

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1 , wherein R 3 and R 4 are joined with the carbon to which they are attached to form a cycloalkyl ring, and the cycloalkyl ring is substituted with one or more fluorine atoms.

3. The compound of claim 1 , wherein R 4 is halogen, phenyl, fluorophenyl, methylphenyl, or cyclohexylmethyl.

4. The compound of claim 1 , wherein R 4 is halogen, fluorophenyl, methylphenyl, or cyclohexylmethyl.

5. The compound of claim 1 , wherein:

R 2 is hydrogen or halogen;

R 3 is hydrogen, —OH, or halogen;

R 4 is halogen, CH 3 , phenyl, fluorophenyl, methylphenyl, or cyclohexylmethyl;

R 7 is —OH; and

R 8 is hydrogen.

6. The compound of claim 1 , wherein:

R 2 is hydrogen or halogen;

R 3 is hydrogen, —OH, or halogen;

R 4 is halogen, CH 3 , or phenyl;

R 7 is —OH; and

R 8 is hydrogen.

7. The compound of claim 1 , wherein:

R 2 is hydrogen or halogen;

R 3 is —OH or halogen;

R 4 is halogen, CH 3 , or phenyl;

R 7 is —OH; and

R 8 is hydrogen.

8. The compound of claim 1 , wherein:

R 2 is hydrogen;

R 3 is —OH or halogen;

R 4 is halogen, CH 3 , or phenyl;

R 7 is —OH; and

R 8 is hydrogen.

9. The compound of claim 1 , wherein:

R 2 is hydrogen or fluorine;

R 3 is fluorine;

R 4 is fluorine, CH 3 , or phenyl;

R 7 is —OH; and

R 8 is hydrogen.

10. A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable carrier.

Assignments (3)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 075494/0030 →
SECURITY INTEREST Recorded Oct 6, 2023
From: AMICUS THERAPEUTICS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 065177/0196 →